Meeting
2019 Gastrointestinal Cancers Symposium
KRAS and TP53 status as a predictor of survival in patients with resected pancreatic ductal adenocarcinoma.
Authors
Caitlin A McIntyre
Memorial Sloan Kettering Cancer Center, New York, NY
Caitlin A McIntyre , Sharon Anita Lawrence , Winston Wong , Joanne F. Chou , Marinela Capanu , Michael F. Berger , Peter Allen , Eileen Mary O'Reilly
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Sub Track
Translational Research
Citation
J Clin Oncol 37, 2019 (suppl 4; abstr 276)
DOI
10.1200/JCO.2019.37.4_suppl.276
Abstract #
276
Poster Bd #
E14
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Mutational landscape of pancreatic adenocarcinoma identified by prospective clinical sequencing in a nationwide cancer network.
First Author: Katherine E Poruk
Poster
2022 ASCO Annual Meeting
Evaluation of stage IV pancreatic adenocarcinomas based on mutational profiling of tumors.
First Author: Katherine E Poruk
Poster
2019 Gastrointestinal Cancers Symposium
The impact of CDKN2A mutations on overall survival in pancreatic adenocarcinoma.
First Author: Allison Doyle
Poster
2016 Gastrointestinal Cancers Symposium
Comprehensive genomic analysis in metastatic pancreatic ductal adenocarcinoma (PDAC).
First Author: Hui-Li Wong